CRISPR Therapeutics AG

CRISPR Therapeutics delivered a sharply disappointing first quarter, missing on both the top and bottom lines as the gene editing company continues to burn cash across a busy pipeline. The company posted an EPS loss of $1.58, missing the consensus estimate of $1.28 by 23.75%, while revenue of just $865,000, composed entirely of grant income with no collaboration revenue recognized, fell 85.50% short of the $5.96 million Wall Street had expected, even as that figure represented 71.6% growth year-over-year. The net loss widened to $136 million from $116.59 million a year earlier, driven in part by higher collaboration expenses tied to CASGEVY and in vivo HSC editing programs. With <a href="https://247wallst.com/investing/2025/05/05/crispr-therapeutics-crsp-short-sellers-have-a-lot-riding-on-earnings/">significant short interest riding on the outcome</a>, the headline numbers were softened by a genuine clinical bright spot: CTX310 demonstrated dose-dependent LDL and triglyceride reductions of up to 81% and 82%, respectively, across its first 10 patients. Management guided for growing CASGEVY patient initiations through 2025 and flagged CTX320 top-line data as a near-term catalyst expected in Q2.